Hemostemix Inc. (CVE:HEM – Get Free Report) shares were down 16.7% during trading on Wednesday . The company traded as low as C$0.14 and last traded at C$0.15. Approximately 310,553 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 520,395 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 7.9 %
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a market cap of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20. The business has a 50 day moving average price of C$0.20 and a 200 day moving average price of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Do ETFs Pay Dividends? What You Need to Know
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Investing in Construction Stocks
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
